Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 1 of 11 for:    bretthauer
Previous Study | Return to List | Next Study

The BALLOON- (BALLOon Treatment for Obesity in Norway) Pilot Study (BALOON Pilot)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03576833
Recruitment Status : Recruiting
First Posted : July 3, 2018
Last Update Posted : July 3, 2018
University of Oslo
Information provided by (Responsible Party):
Michael Bretthauer, Oslo University Hospital

Brief Summary:

This protocol describes a feasibility pilot study preceding a randomized clinical study that aims at comparing the Elipse intragastric Balloon system to other invasive obesity techiniques.

The current pilot study is investigating the feasibility and efficacy of the Elipse Balloon system in 20 patients in Norway.

Condition or disease Intervention/treatment Phase
Obesity Device: Elipse Balloon system Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The BALLOON- (BALLOon Treatment for Obesity in Norway) Pilot Study
Actual Study Start Date : May 15, 2018
Estimated Primary Completion Date : June 1, 2019
Estimated Study Completion Date : December 31, 2019

Arm Intervention/treatment
Experimental: Balloon Device: Elipse Balloon system
intragastic balloon

Primary Outcome Measures :
  1. Feasibility [ Time Frame: 4 months ]
    percentage of adequate balloon insertion and balloon excretion

Secondary Outcome Measures :
  1. Efficacy [ Time Frame: 4 months ]
    Weight in kg during intervention, and HBA1c values compared to baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adults 18 year or older with BMI ≥30 and ≤40 kg/m2, and a diagnosis of type 2 diabetes.

Exclusion Criteria:

  1. Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease
  2. Previous bariatric or gastric surgery
  3. History of chronic or acute pancreatitis
  4. History of small bowel obstructions
  5. History of open abdominal and/or pelvic surgery EXCLUDING open appendectomy with a right lower quadrant incision.
  6. Thyroid or adrenal disease not controlled with medication
  7. History of/or signs and/or symptoms of esophageal, gastric, or duodenal disease such as dysphagia and/or painful swallowing, hiatal hernias >5 centimeter, paraesophageal hernias, chronic or acute inflammation, cancer, varices, diverticula, gastroparesis, ulcers, stricture/stenosis, or achalasia
  8. Specific diagnosed genetic or hormonal cause for obesity such as Prader-Willi syndrome
  9. Severe coagulopathy, hepatic insufficiency or cirrhosis
  10. Unable or unwilling to discontinue use of aspirin and/or non-steroidal anti-inflammatory agents (NSAIDs) at least 14 days prior to Elipse deployment and continuing for 14 days after Elipse excretion
  11. Anemia defined as either Hgb <11 g/dL for females and <12 g/dL for males
  12. Inability to walk 200 meters without assistance
  13. Eating disorders including night eating syndrome (NES), bulimia, or binge eating disorder
  14. Current or history of illicit drug use or excessive alcohol use
  15. Currently taking the following medications (within 30 days prior to enrolment) and/or anticipated need for these medications during the study: Systemic corticosteroids; anticoagulants (e.g. warfarin, dabigatran) or anti-platelet therapy; narcotics or opiates; anti-seizure medication (e.g. clonazepam, phenytoin)
  16. Serum autoantibodies against glutamic acid decarboxylase (GAD) or tyrosine phosphatase (IA2) (MODY or type 1 diabetes)
  17. Any specified conditions that, in the opinion of the investigator, may render the subject unable to complete the study without a likely fatal outcome, or lead to difficulties for subject compliance with study requirements, or could confound study data.
  18. Women in childbearing age must document a negative pregnancy test. Women must not be breast-feeding at the time of treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03576833

Layout table for location contacts
Contact: Michael Bretthauer, MD PhD 90132480
Contact: Christer Tønnesen, MD

Layout table for location information
Oslo University Hospital Recruiting
Oslo, Norway, 0318
Contact: Christer Tønnesen, MD   
Sponsors and Collaborators
Norwegian Department of Health and Social Affairs
University of Oslo

Layout table for additonal information
Responsible Party: Michael Bretthauer, Professor, Oslo University Hospital Identifier: NCT03576833    
Other Study ID Numbers: REK 2017/1574
First Posted: July 3, 2018    Key Record Dates
Last Update Posted: July 3, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Body Weight
Signs and Symptoms